Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5743-5748

  Bhandarkar, Sulochana S ^a   Bromberg, Jacqueline ^c   Carrillo, Carol ^a   Selvakumar, Ponniah ^d   Sharma, Rajendra K ^d   Perry, Betsy N ^a   Govindarajan, Baskaran ^a   Fried, Levi ^a   Sohn, Allie ^a   Reddy, Kalpana ^a   Arbiser, Jack L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN N MYRISTOYLTRANSFERASE; PROTEIN N MYRISTOYLTRANSFERASE INHIBITOR; S6 KINASE; STAT3 PROTEIN; TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM; UNCLASSIFIED DRUG; VASCULOTROPIN; ACYLTRANSFERASE; GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE; ORGANOMETALLIC COMPOUND; PALLADIUM;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CANCER TRANSPLANTATION; DRUG ANTAGONISM; DRUG SCREENING; EXPERIMENTAL MELANOMA; NUDE MOUSE; TUMOR CELL LINE;

ACYLTRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; PALLADIUM;

EID: 53249101817     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0405     Document Type: Article

References (46)

1. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell 2002;2:5-7.
2. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33;19-20.
3. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002;8:3728-33.
4. Govindarajan B, Bai X, Cohen C, et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003; 278:9790-5.
5. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005;65: 2412-21.
6. Dhawan P, Richmond A. A novel NF-κB-inducing kinase-MAPK signaling pathway up-regulates NF-κB activity in melanoma cells. J Biol Chem 2002;277: 7920-8.
7. Selzer E, Thallinger C, Hoeller C, et al. Betulinic acidinduced Mcl-1 expression in human melanoma-mode of action and functional significance. Mol Med 2002; 8:877-84.
8. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and β-catenin pathways. Cancer Res 2001;61:7318-24.
9. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res 2002;62:7335-42.
10. Soengas MS, Gerald WL, Cordon-Cardo C, Lazebnik Y, Lowe SW. Apaf-1 expression in malignant melanoma. Cell Death Differ 2006;13:352-3.
11. Bhoumik A, Gangi L, Ronai Z. Inhibition of melanoma growth and metastasis by ATF2-derived peptides. Cancer Res 2004;64:8222-30.
12. Shattuck-Brandt RL, Richmond A. Enhanced degradation of I-κB α contributes to endogenous activation of NF-κB in Hs294T melanoma cells. Cancer Res 1997;57:3032-9.
13. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-κB activity. Cytokines Cell MolTher 2000;6:9-17.
14. Karakousis CP, Getaz EP, Bjornsson S, et al. cis - Dichlorodiammineplatinum(11) and DTIC in malignant melanoma. Cancer Treat Rep1979;63:2009-10.
15. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.
16. Arbiser JL. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms. Semin Cancer Biol 2004;14:81-91.
17. Cerimele F, BattleT, Lynch R, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A 2005;102:175-9.
18. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005;103:2584-9.
19. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005; 23:6107-16.
20. Arbiser JL, Klauber N, Rohan R, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998;4: 376-83.
21. Robinson TP, EhlersT, Hubbard RB IV, et al. Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg Med Chem Lett 2003;13:115-7.
22. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002;62:3868-75.
23. Khor TO, Keum YS, Lin W, et al. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res 2006;66:613-21.
24. Bai X, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003;278:35501-7.
25. Arbiser JL, Panigrathy D, Klauber N, et al. The antiangiogenic agentsTNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999;40:925-9.
26. Raju RV, MoyanaTN, Sharma RK. Overexpression of human N-myristoyltransferase utilizing a T7 polymerase gene expression system. Protein Expr Purif 1996;7:431-7.
27. King MJ, Sharma RK. N-myristoyltransferase assay using phosphocellulose paper binding. Anal Biochem 1991;199:149-53.
28. King MJ, Sharma RK. Identification, purification and characterization of a membrane-associated N-myristoyltransferase inhibitor protein from bovine brain. Biochem J 1993;291:635-9.
29. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 2003;4:95-8.
30. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006;12:2301-7s.
31. Tsao H, Zhang X, Benoit E, Haluska FG. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines. Oncogene1998;16:3397-402.
32. Teng DH, Hu R, Lin H, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997;57:5221-5.
33. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon a and chemotherapy. Semin Oncol 1997;24:S39-43.
34. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatoryTcells in cancer patients. Blood 2006;107:2409-14.
35. Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 2006;29: 455-63.
36. Margolin KA, Liu PY, Unger JM, et al. Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. J Cancer Res Clin Oncol 1999;125:292-6.
37. Lewis KD, Gibbs P, O'Day S, et al. A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF Cancer Invest 2005;23:303-8.
38. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12:2353-8s.
39. Margolin K, Longmate J, BarattaT, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8.
40. Larribere L, Khaled M, Tartare-Deckert S, et al. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 2004;11:1084-91.
41. Burdelya L, Kujawski M, Niu G, et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol 2005;174:3925-31.
42. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-42.
43. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A 1997; 94:861-6.
44. Gabrilovich Dl, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
45. Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κ B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-32.
46. Sun SY, Rosenberg LM, Wang X, et al. Activation on Akt and elF4E survival pathways by repamycinmediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8.